You have 9 free searches left this month | for more free features.

Calquence

Showing 1 - 25 of 54

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance

Not yet recruiting
  • Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)
    • (no location specified)
    Dec 16, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,

    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • +3 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Dec 19, 2022

    Bioequivalence Trial in Glendale, Brooklyn, Salt Lake City (Treatment A: Acalabrutinib tablet, Treatment B: Acalabrutinib

    Completed
    • Bioequivalence
    • Treatment A: Acalabrutinib tablet
    • Treatment B: Acalabrutinib capsule
    • Glendale, California
    • +2 more
    Jul 7, 2022

    DLBCL Trial (Acalabrutinib, Rituximab)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • (no location specified)
    Jul 11, 2023

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 14, 2022

    Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)

    Recruiting
    • Mantle Cell Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 22, 2022

    Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance

    Active, not recruiting
    • Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
      • Aichi, Japan
      • +48 more
      Dec 7, 2022

      Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

      Recruiting
      • Mantle Cell Lymphoma
      • Refractory Lymphoma
      • Boston, Massachusetts
      • +1 more
      Aug 8, 2022

      Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)

      Recruiting
      • Chronic Lymphocytic Leukemia (CLL)
      • Boston, Massachusetts
        Dana-Farber Cancer Institute
      May 13, 2022

      Chronic Lymphocytic Leukemia, CLL/SLL Trial in New York (Acalabrutinib)

      Withdrawn
      • Chronic Lymphocytic Leukemia
      • CLL/SLL
      • New York, New York
        Weill Cornell Medicine
      Mar 25, 2022

      Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

      Not yet recruiting
      • Recurrent Chronic Lymphocytic Leukemia
      • +3 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jan 10, 2023

      Food Allergy, Food Allergy Peanut Trial in Baltimore (Acalabrutinib)

      Recruiting
      • Food Allergy
      • Food Allergy Peanut
      • Baltimore, Maryland
        Johns Hopkins Bayview Medical Center
      Dec 30, 2021

      Acalabrutinib in Chronic Lymphocytic Leukaemia in United Kingdom

      Recruiting
      • Chronic Lymphocytic Leukemia, CLL
      • Aylesbury, United Kingdom
      • +7 more
      Jan 12, 2023

      Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Saint Louis (Durvalumab, Acalabrutinib)

      Recruiting
      • Primary Central Nervous System Lymphoma
      • Secondary Central Nervous System Lymphoma
      • Saint Louis, Missouri
        Washington University School of Medicine
      Mar 14, 2022

      CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)

      Recruiting
      • Central Nervous System Lymphoma
      • Chapel Hill, North Carolina
      • +1 more
      Mar 24, 2022

      Chronic Lymphocytic Leukemia (CLL) Trial in United States (Venetoclax, Obinutuzumab, Acalabrutinib)

      Active, not recruiting
      • Chronic Lymphocytic Leukemia (CLL)
      • Stamford, Connecticut
      • +4 more
      Dec 2, 2022

      Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

      Recruiting
      • Chronic Lymphocytic Leukemia
      • Small Lymphocytic Lymphoma
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Nov 2, 2022

      Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

      Recruiting
      • Blastoid Variant Mantle Cell Lymphoma
      • +8 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 5, 2022

      Waldenstrom Macroglobulinemia Trial in Canada (Acalabrutinib, Bendamustine, Rituximab)

      Recruiting
      • Waldenstrom Macroglobulinemia
      • Calgary, Alberta, Canada
      • +8 more
      Nov 9, 2022

      Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

      Recruiting
      • Chronic Lymphocytic Leukemia
      • +2 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Jan 4, 2023

      Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)

      Active, not recruiting
      • Mantle Cell Lymphoma
      • Saint Louis, Missouri
        Washington University School of Medicine
      Feb 2, 2022

      Mantle Cell Lymphoma Trial in New York (Acalabrutinib, Lenalidomide, Rituximab)

      Recruiting
      • Mantle Cell Lymphoma
      • New York, New York
        Weill Cornell Medicine
      Oct 29, 2021

      Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)

      Active, not recruiting
      • Chronic Lymphocytic Leukemia
      • Boston, Massachusetts
      • +2 more
      Aug 19, 2022

      Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma Trial in India (Acalabrutinib capsule)

      Active, not recruiting
      • Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
      • Acalabrutinib capsule
      • Ahmedabad, India
      • +12 more
      Feb 2, 2023